Novel ADC and immunotherapy combo shows promise in endometrial cancer subtype

In a small, investigator-initiated Phase II study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination…
Read More

"The only truly secure system is one that is powered off, cast in a block of concrete and sealed in a lead-lined room with armed guards." — Gene Spafford

Ante penatibus urna conubia pharetra nulla placerat orci etiam. Finibus faucibus tempus vivamus lorem nulla orci posuere augue donec. Cras pellentesque a vel posuere condimentum in pulvinar facilisis bibendum. Id bibendum maximus luctus si nam lectus congue tempor ex. Lorem turpis natoque tempus curabitur duis felis venenatis convallis.

Post tags :